Episode
New GLP-1 Drug Options and More Highlights From the ADA's 2026 Scientific Sessions
- Podcast
- JAMA Medical News
- Published
- Jun 18, 2026
- Duration seconds
- 1369
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/jama-medical-news-779603/episodes/new-glp-1-drug-options-and-more-highlights-from-the-ada-s-2026-scientific-sessions/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/jama-medical-news-779603/new-glp-1-drug-options-and-more-highlights-from-the-ada-s-2026-scientific-sessions.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Rita Kalyani, MD, chief scientific and medical officer at the American Diabetes Association, discusses the latest diabetes and obesity research, including a novel oral GLP-1 drug, a combined semaglutide-amylin analogue injection, data from China on high-dose mazdutide, and more. Related Content: A New GLP-1 Pill for Diabetes, Semaglutide With Amylin, Data From China, and More From ADA 2026